The European Commission (EC), the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published the 2022-2026 workplan of the Accelerate Clinical Trials in the EU (ACT EU) initiative. The workplan has been prepared based on the recommendations of the European medicines’ agencies network strategy to 2025 and the European Commission’s Pharmaceutical Strategy for Europe.
The initiative launched in January just before the Clinical Trials Regulation (CTR) became applicable and seeks to promote the development of high-quality, safe and effective medicines by strengthening the European clinical trials environment. The workplan is structured in line with the ten priority actions of ACT EU and highlights key focus areas, such as innovation in clinical trials, robust methodologies, and collaboration across stakeholders.
Read the full work plan here.
Read more details here.
Disclaimers
- The material in these reviews is from various public open access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
